Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights
Phase 1/2 Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Ongoing; Study Startup ActivitiesProgressing for Phase 1/2 Trials of […]
MTBC Reports Record First Quarter 2020 Revenue
Company Reports 45% GrowthSOMERSET, N.J., May 14, 2020 (GLOBE NEWSWIRE) — MTBC, Inc. (the “Company” or “MTBC”) (Nasdaq: MTBC) (Nasdaq: […]
BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
NEW HAVEN, Conn., May 14, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical […]
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing Platform ~~ New Non-Human Primate Data […]
LHC Group to present at two virtual healthcare conferences in May
LAFAYETTE, La., May 14, 2020 (GLOBE NEWSWIRE) — LHC Group, Inc. (NASDAQ: LHCG) announced today that the Company is presenting […]
Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting
Virtual oral presentation reviews interim clinical biomarker data for SGT-001 and provides data on expression and co-localization of microdystrophin and […]
Plug Power Inc. Announces Pricing of Offering of $200.0 Million of Convertible Senior Notes
LATHAM, N.Y., May 14, 2020 (GLOBE NEWSWIRE) — Plug Power Inc. (“Plug Power”) (NASDAQ: PLUG) today announced the pricing of […]
Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program
– Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients –Conference […]
HOOKIPA Pharma Reports First Quarter 2020 Financial Results and Provides a Corporate Update
NEW YORK and VIENNA, Austria, May 14, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing […]
TCR² Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated […]
